This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: F. Hoffmann-La Roche Ag. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Claudio Murgia - Innovator in Combination Therapies
Introduction
Claudio Murgia is an inventor based in Baden, Switzerland. He is known for his work in the field of combination therapies, particularly in the treatment of cancer. His innovative approach focuses on the use of PD-1 axis binding antagonists in conjunction with LRRK2 inhibitors.
Latest Patent Applications
Claudio Murgia has submitted a patent application titled "COMBINATION THERAPY OF PD-1 AXIS BINDING ANTAGONISTS AND LRRK2 INHIBITORS." This application outlines a novel approach to cancer treatment by employing these combination therapies. The invention aims to enhance the efficacy of cancer treatments through the synergistic effects of the mentioned compounds.
Conclusion
Claudio Murgia's contributions to the field of combination therapies represent a significant step forward in cancer treatment. His innovative ideas have the potential to improve patient outcomes and advance medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile